Scotiabank Keeps Their Hold Rating on Syndax Pharmaceuticals (SNDX)
TipRanks · 7h ago
Buy Rating Affirmed for Syndax Pharmaceuticals Amidst Upcoming Product Launches and Promising Clinical Advances
TipRanks · 7h ago
Buy Rating Affirmed for Syndax Pharmaceuticals Amid Strong Clinical Results and Solid Financial Outlook
TipRanks · 8h ago
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT), Natera (NTRA) and Syndax Pharmaceuticals (SNDX)
TipRanks · 9h ago
Barclays Issues a Buy Rating on Syndax Pharmaceuticals (SNDX)
TipRanks · 11h ago
Syndax Pharmaceuticals Poised for Growth: A Buy Rating Analysis
TipRanks · 11h ago
Analysts’ Top Healthcare Picks: PROCEPT BioRobotics (PRCT), Pliant Therapeutics (PLRX)
TipRanks · 16h ago
Incyte's Axatilimab Receives FDA Priority Review For Chronic Graft-Versus-Host Disease Treatment
NASDAQ · 17h ago
Syndax Pharmaceuticals Expects $600M In Cash And Equivalents To Provide Runway Through 2026;
For the first quarter of 2024, the company expects research and development expenses to be $56 to $62 million. The company expects operating expenses for the full year of 2024 to be in the range of $355 to $375 million. The company also expects to be profitable in 2024.
Benzinga · 20h ago
FDA accepts Incyte application for graft-versus-host disease drug
Healthcare FDA accepts Incyte application for graft-versus-host disease drug. The agency is expected to issue a decision on the application by Aug. 28. Axatilimab is being developed with Syndax Pharmaceuticals (NASDAQ:SNDX)
Seeking Alpha · 21h ago
Syndax Pharmaceuticals: Q4 Earnings Insights
Syndax Pharmaceuticals reported its Q4 earnings on February 27, 2024. The company missed estimates by -1.0%. The company's revenue was down $0 from the same period last year. Last quarter the company beat on EPS by $0.05.
Benzinga · 22h ago
Syndax Pharmaceuticals GAAP EPS of -$1.00 misses by $0.04
Seeking Alpha · 22h ago
Notable earnings after Tuesday's close
Seeking Alpha · 1d ago
Earnings Preview: Syndax Pharmaceuticals
Syndax Pharmaceuticals is set to give its latest quarterly earnings report on Tuesday. Analysts estimate the company will report an earnings per share of $-0.99. Last quarter the company beat EPS by $0.05. The company's shares are down 5.92% in the last 52 weeks.
Benzinga · 2d ago
Syndax (SNDX) is on the Move, Here's Why the Trend Could be Sustainable
NASDAQ · 2d ago
Webull provides a variety of real-time SNDX stock news. You can receive the latest news about Syndax Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About SNDX
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on developing a pipeline of cancer therapies. The Company’s lead product candidates include SNDX-5613 (revumenib) and SNDX-6352 (axatilimab). It is focused on developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, also known as mixed lineage leukemia rearranged (MLLr), acute leukemias including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), and nucleophosmin 1 (NPM1) mutant AML. Its axatilimab, is a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis (IPF). Its products candidate also includes entinostat, an oral, small molecule and Class I histone deacetylases (HDAC) inhibitor that has direct effects on both cancer cells and immune regulatory cells.